What does the whole evidence base look like?
Four primary papers carry essentially all of it, and they are not equal in weight. Two are human pharmacodynamic trials of CJC-1295 with DAC. [1][2] One is an animal and cell-culture pharmacology paper on ipamorelin. [3] One is a human phase 2 efficacy trial of ipamorelin that did not meet its primary endpoint. [4]
Evidence level is a way of ranking how much a given study design can tell us. Human randomised, placebo-controlled trials sit near the top because they compare a treated group with an untreated group under blinded conditions, reducing the chance that a result is due to expectation or chance. Animal and cell-culture studies sit lower for questions about human effects, not because the science is weak, but because a rat pituitary cell or a swine model cannot fully stand in for a human being. Reading the table below with those distinctions in mind is more informative than counting citations.
| Source | Evidence level | Population | Key result |
|---|---|---|---|
| Teichman 2006 [1] | Human, randomised, placebo-controlled | Healthy adults 21–61 | Half-life 5.8–8.1 days; GH up 2–10-fold; IGF-I up 1.5–3-fold |
| Ionescu 2006 [2] | Human pharmacodynamics | Healthy men 20–40 | Trough GH up 7.5-fold; mean GH up 46%; IGF-I up 45%; pulsatility preserved |
| Raun 1998 [3] | In vitro and animal | Rat cells, rats, swine | Selective GH release; no ACTH or cortisol rise at >200× ED50 |
| Beck 2014 [4] | Human, phase 2 RCT | 117 enrolled after bowel resection | Primary endpoint missed: 25.3 h vs 32.6 h, p=0.15 |
Three of the four studies test a single component, and the fourth tests ipamorelin in a surgical recovery indication. None tests the pairing.
What is actually established?
- CJC-1295 with DAC produces prolonged GH and IGF-I elevation in healthy adults, with a half-life of 5.8 to 8.1 days. [1]
- Pulsatile GH release is preserved under that stimulus; the rise in IGF-I tracks the higher trough rather than larger pulses. [2]
- Ipamorelin releases GH selectively in rat and swine models without raising ACTH, cortisol, FSH, LH, prolactin or TSH. [3]
- In the one published human efficacy trial, ipamorelin did not significantly shorten time to tolerating solid food after bowel surgery. [4]
That is a genuine but narrow body of knowledge. It describes hormone concentrations in healthy volunteers over weeks and receptor selectivity in animals. It does not describe body composition, performance, recovery, long-term safety, or any outcome over months.
It is worth restating why that distinction matters. A hormone-concentration study answers the question “did GH and IGF-I go up, and for how long, and was that safe over the study period.” It does not answer the question “did anything downstream of that hormone change — muscle, fat, sleep, recovery — actually change, and by how much.” Both questions are legitimate; only the first one has been answered here.
What is missing?
- Any published human trial of CJC-1295 without DAC.
- Any published human trial of CJC-1295 and ipamorelin given together.
- Any phase 3 programme for either compound.
- Long-term safety data beyond the 28- to 49-day windows of the published trials. [1]
- Outcome endpoints of any kind for the combination.
Saying this plainly is more useful than filling the gaps with mechanism. The convergence of two secretory pathways is a reason to design a trial; it is not a finding.
It also means claims about ratios, timing and cycling for the blend have no study behind them. Where a number has no source, the correct action is to leave it out.
What do the studies say about tolerability?
The CJC-1295 ascending-dose trials reported no serious adverse reactions, with the best tolerability at 30 and 60 micrograms per kilogram. [1] Detailed adverse-event tables are not reproduced in the accessible abstract, so no incidence percentages are quoted here.
The ipamorelin phase 2 trial reported treatment-emergent adverse events in 87.5% of the ipamorelin group and 94.8% of the placebo group, and concluded the compound was well tolerated. [4] A high event rate in both arms is normal in a postoperative population and is one reason placebo data must always be shown alongside treatment data.
Tolerability in a 28- to 49-day healthy-volunteer study is not a long-term safety profile, and no study in this set was designed to produce one.
What research would settle the open questions?
A trial of the combination would need to specify the exact CJC-1295 form, the ipamorelin identity and ratio, the schedule, the population, and a comparator design capable of separating the pairing from each component alone. It would need prespecified endpoints and full adverse-event and withdrawal reporting, followed by independent replication.
Until something like that is published, the accurate summary is that two components have partial evidence of different kinds and the combination has none.
For the form-specific detail behind the CJC-1295 figures, read CJC-1295 with DAC versus without DAC.
Frequently Asked Questions
Is there any positive human efficacy trial for either compound?
No. The human CJC-1295 studies measured hormone concentrations, not clinical outcomes, and the human ipamorelin trial missed its primary endpoint.
Does pathway convergence prove synergy?
No. Synergy requires a study designed to detect it against each component alone.
Why is the null ipamorelin trial included here?
Leaving out unfavourable results would misrepresent the evidence base.
Do animal potency values translate to humans?
Not directly. The rat and swine ED50 values describe those species under those protocols.
